Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.6K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.6K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

655
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
655
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

444
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
444
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

482
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
482
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular and clinical characterization of nut, peanut, and seed allergies: the role of seed storage proteins.

European annals of allergy and clinical immunology·2025
Same author

A clinical update on chronic rhinosinusitis and nasal polyposis.

European annals of allergy and clinical immunology·2025
Same author

Quartic solitons of a mode-locked laser distributed model.

Optics letters·2023
Same author

Relevance of the diagnosis of hypersensitivity reactions to antineoplastic and biological agents: experience with drug provocation test.

European annals of allergy and clinical immunology·2023
Same author

Anaphylactic Shock to Lidocaine: A Rare Case With Evaluation of Cross-Reactivity Between Local Anesthetics.

Journal of investigational allergology & clinical immunology·2021
Same author

Portuguese version of Parent-reported Drug Hypersensitivity Quality of Life Questionnaire (P-DrHy-Q): assessment of reliability and validity.

European annals of allergy and clinical immunology·2021

Related Experiment Video

Updated: May 1, 2026

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

3.7K

Desensitization to clopidogrel: a tailor-made protocol.

P Barreira1, S Cadinha2, D Malheiro2

  • 1Drug Allergy Unit, Allergy and Clinical Immunology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho - EPE, Vila Nova de Gaia, Portugal. pccb23@gmail.com.

European Annals of Allergy and Clinical Immunology
|April 8, 2014
PubMed
Summary
This summary is machine-generated.

This case study demonstrates successful desensitization to clopidogrel, an antiplatelet medication, in a patient experiencing a delayed hypersensitivity reaction. A slower, individualized desensitization protocol enabled the patient to tolerate the necessary dosage for cardiovascular disease management.

Keywords:
Clopidogreldesensitizationhypersensitivity reaction

More Related Videos

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Related Experiment Videos

Last Updated: May 1, 2026

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

3.7K
Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.7K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Area of Science:

  • Cardiology
  • Clinical Pharmacology
  • Immunology

Background:

  • Clopidogrel is a crucial antiplatelet agent for managing cardiovascular diseases.
  • Hypersensitivity reactions to clopidogrel, though uncommon, can necessitate alternative treatment strategies.

Observation:

  • A 70-year-old male developed a delayed hypersensitivity reaction, characterized by swelling and skin lesions, after initiating clopidogrel therapy.
  • Initial desensitization attempts were complicated by recurrent cutaneous manifestations.

Findings:

  • A modified, gradual desensitization protocol over two months successfully enabled the patient to achieve and maintain the therapeutic dose of clopidogrel (75 mg/d).
  • This slower approach, tailored to patient response, proved effective in managing delayed hypersensitivity reactions.

Implications:

  • Clopidogrel desensitization is a viable and safe option for patients with hypersensitivity reactions, particularly those with delayed cutaneous presentations.
  • Individualized, slower desensitization protocols may be essential for managing complex hypersensitivity reactions to antiplatelet drugs.